• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Artivion Inc.

    9/26/22 2:55:57 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email
    SC 13D 1 b926223sc13d.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

    Artivion, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    228903100

    (CUSIP Number)

     

    John A. Bartholdson

    Juniper Investment Company, LLC

    555 Madison Avenue, 24th Floor

    New York, New York 10022

    (212) 339-8500

     

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    September 23, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box o.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

       
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 2 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper Targeted Opportunity Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    1,473,656

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    1,473,656

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,473,656

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.7%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

     Page 2 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 3 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper HF Investors II, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    1,473,656

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    1,473,656

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,473,656

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.7%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

     Page 3 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 4 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper Targeted Opportunities, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    606,808

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    606,808

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    606,808

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.5%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

     Page 4 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 5 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper Targeted Opportunity Investors, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    606,808

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    606,808

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    606,808

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.5%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

     Page 5 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 6 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper Multi-Strategy Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    10,400

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    10,400

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,400

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.0%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

     Page 6 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 7 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper HF Investors, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    10,400

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    10,400

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    10,400

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.0%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

     Page 7 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 8 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Juniper Investment Company, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    2,090,864

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    2,090,864

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,090,864

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.2%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IA

     

     Page 8 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 9 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Alexis P. Michas

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    OO

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    2,090,864

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    2,090,864

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,090,864

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.2%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

     Page 9 of 17 Pages 
     

     

    SCHEDULE 13D

     

    CUSIP No.  228903100   Page 10 of 17 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    John A. Bartholdson

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

     

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    OO

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     

    o
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    2,090,864

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    2,090,864

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,090,864

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     

    o
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.2%

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

     Page 10 of 17 Pages 
     

     

    Item 1.Security and Issuer.

     

    This statement on Schedule 13D (this “Schedule 13D”) relates to the Common Stock, $0.01 par value per share (the “Shares”), of Artivion, Inc., a Delaware Corporation (the “Issuer”). The principal executive office of the Issuer is located at 1655 Roberts Boulevard, NW, Kennesaw, Georgia 30144. The Shares are listed on the New York Stock Exchange under the ticker symbol “AORT”. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    Item 2.Identity and Background.

     

    (a)       This Schedule 13D is being filed by:

     

    (i)       Juniper Targeted Opportunity Fund, L.P., a Delaware limited partnership (“Juniper Fund”);

     

    (ii)       Juniper HF Investors II, LLC, a Delaware limited liability company and the general partner of Juniper Fund (“Juniper HF II”);

     

    (iii)       Juniper Targeted Opportunities, L.P., a Delaware limited partnership (“Juniper Targeted Opportunities”);

     

    (iv)       Juniper Targeted Opportunity Investors, LLC, a Delaware limited liability company and the general partner of Juniper Targeted Opportunities (“Juniper TO”);

     

    (v)       Juniper Multi-Strategy Fund, L.P., a Delaware limited partnership (Juniper Multi-Strategy”);

     

    (vi)       Juniper HF Investors, LLC, a Delaware limited liability company and the general partner of Juniper Multi-Strategy (“Juniper HF”);

     

    (vii)       Juniper Investment Company, LLC, a Delaware limited liability company and the investment advisor to Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy (“Juniper Investment Company”);

     

    (viii)       Alexis P. Michas, as a managing member of each of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company; and

     

    (ix)       John A. Bartholdson, as a managing member of each of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company.

     

    Each of the foregoing is referred to herein as a “Reporting Person” and together as the “Reporting Persons.”

     

    (b)       The principal business address of each of the Reporting Persons is 555 Madison Avenue, 24th Floor, New York, New York 10022.

     

     Page 11 of 17 Pages 
     

     

    (c)       The principal business of each of Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy is to invest in the capital stock of various companies. The principal business of Juniper HF II is to serve as the general partner of Juniper Fund. The principal business of Juniper TO is to serve as the general partner of Juniper Targeted Opportunities. The principal business of Juniper HF is to serve as the general partner of Juniper Multi-Strategy. Juniper Investment Company provides investment advisory and management services and acts as the investment manager of Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy. Each of Messrs. Michas and Bartholdson serves as the managing member of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company.

     

    (d)       During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)       During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)       Each of Messrs. Michas and Bartholdson is a United States citizen.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    The Shares held by the Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy that are the subject of this Schedule 13D were purchased with available working capital of the Reporting Persons, including capital contributions from investors in Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy. Such Shares were purchased in open market purchases for an aggregate purchase price of approximately $33,636,700, including brokerage commissions.

     

    Item 4.Purpose of Transaction.

     

    The Shares acquired by the Reporting Persons have been acquired for the purpose of making an investment in the Issuer. Each of the Reporting Persons intends to review its investment on a regular basis and, as a result thereof, may at any time or from time to time determine, either alone or as part of a group, (a) to acquire additional securities of the Issuer, through open market purchases, privately negotiated transactions or otherwise, (b) to dispose of all or a portion of the securities of the Issuer owned by it in the open market, in privately negotiated transactions or otherwise, or (c) to take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results described in the next paragraph of this Item 4. Any such acquisition or disposition or other transaction would be made in compliance with all applicable laws and regulations. Notwithstanding anything contained herein, each of the Reporting Persons specifically reserves the right to change its intention with respect to any or all of such matters. In reaching any decision as to its course of action (as well as to the specific elements thereof), each of the Reporting Persons currently expects that it would take into consideration a variety of factors, including, but not limited to, the following: the Issuer’s business and prospects; other developments concerning the Issuer and its businesses generally; other business opportunities available to the Reporting Persons; changes in law and government regulations; general economic conditions; and money and stock market conditions, including the market price of the securities of the Issuer. In addition, in connection with their review of their investment, the Reporting Persons have had and may from time to time seek to engage in communications with one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the board of directors of the Issuer regarding the Issuer.

     

     Page 12 of 17 Pages 
     

     

    Other than as set forth in this Schedule 13D, the Reporting Persons have no present plans or proposals which relate to or would result in any of the matters set forth in clauses (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5.Interest in Securities of the Issuer.

     

    The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.

     

    (a)       The percentages of ownership indicated in this Schedule 13D are calculated based on 40,316,054 Shares of Common Stock, par value $0.01 per share, reported as outstanding as of July 29, 2022 (the “Record Date”), in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, as filed with the United States Securities and Exchange Commission on August 5, 2022.

     

    As of the date of this Schedule 13D, the Reporting Persons collectively held an aggregate of 2,090,864 Shares, constituting approximately 5.2% of the Issuer’s outstanding Shares as of the Record Date. As of the date of this Schedule 13D, each Reporting Person may be deemed to have direct beneficial ownership of the Shares as follows:

     

    (i)       Juniper Fund beneficially owned 1,473,656 Shares, constituting approximately 3.7% of the Issuer’s outstanding Shares as of the Record Date.

     

    (ii)       Juniper Targeted Opportunities beneficially owned 606,808 Shares, constituting approximately 1.5% of the Issuer’s outstanding shares as of the Record Date.

     

    (iii)       Juniper Multi-Strategy beneficially owned 10,400 Shares, constituting approximately 0.0% of the Issuer’s outstanding shares as of the Record Date.

     

    (iv)       Juniper HF II, as the general partner of Juniper Fund, may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 1,473,656 Shares held by Juniper Fund, constituting approximately 3.7% of the Issuer’s outstanding Shares as of the Record Date. Juniper HF II disclaims beneficial ownership of such Shares for all other purposes.

     

    (v)       Juniper TO, as the general partner of Juniper Targeted Opportunities, may be deemed to beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 606,808 Shares held by Juniper Targeted Opportunities, constituting approximately 1.5% of the Issuer’s outstanding Shares as of the Record Date. Juniper TO disclaims beneficial ownership of such Shares for all other purposes.

     

     Page 13 of 17 Pages 
     

     

    (vi)       Juniper HF, as the general partner of Juniper Multi-Strategy, may be deemed to beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 10,400 Shares held by Juniper Multi-Strategy, constituting approximately 0.0% of the Issuer’s outstanding Shares as of the Record Date. Juniper HF disclaims beneficial ownership of such Shares for all other purposes.

     

    (vii)       Juniper Investment Company, as the investment advisor of Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy, may be deemed to own beneficially (as that term is defined in Rule 13-d under the Securities Exchange Act of 1934) the 2,090,864 Shares collectively and directly held by each of Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy, constituting approximately 5.2% of the Issuer’s outstanding Shares as of the Record Date. Juniper Investment Company disclaims beneficial ownership of such Shares for all other purposes.

     

    (viii)       Each of Messrs. Michas and Bartholdson, as the managing member of Juniper HF II, Juniper TO, Juniper HF, and Juniper Investment Company, may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the 2,090,864 Shares held by Juniper Fund, Juniper Targeted Opportunities, Juniper Multi-Strategy, and Juniper Investment Company, constituting approximately 5.2% of the then outstanding Shares. Each of Messrs. Michas and Bartholdson disclaims beneficial ownership of such Shares for all other purposes.

     

    (b)       Each of Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy has the sole power to vote or direct their respective vote of 1,473,656, 606,808, and 10,400 Shares and the sole power to dispose or direct the disposition of such Shares. Juniper HF II, Juniper TO, Juniper HF, Juniper Investment Company, and each of Messrs. Michas and Bartholdson may be deemed to share with Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy, as applicable, the power to vote or to direct the vote and to dispose or to direct the disposition of such Shares.

     

    (c)       Set forth on Exhibit A to this Schedule 13D is a list of transactions in the Shares effected by the Reporting Persons in the past sixty days. These transactions were all effected in the open market through a broker. Except for the foregoing, no other transactions in the Shares were effected by the Reporting Persons during the sixty days prior to the date of this Schedule 13D.

     

    (d)       To the knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares that are the subject of this Schedule 13D.

     

    (e)       Not applicable.

     

     Page 14 of 17 Pages 
     

     

    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    The response to Item 3 is incorporated herein by reference.

     

    Except as described in this Schedule 13D or incorporated by reference in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between any of the Reporting Persons or between any of the Reporting Persons and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

     

    Item 7.Materials to be Filed as Exhibits.

     

    Exhibit A:     Schedule of Transactions

    Exhibit B:     Joint Filing Agreement

     

     Page 15 of 17 Pages 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 26, 2022

     

      JUNIPER TARGETED OPPORTUNITY FUND, L.P.
       
     

    By: Juniper HF Investors II, LLC, its

    General Partner

       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER HF INVESTORS II, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER TARGETED OPPORTUNITIES, L.P.
       
      By: Juniper Targeted Opportunity Investors, LLC, its General Partner
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER TARGETED OPPORTUNITY INVESTORS, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER MULTI-STRATEGY FUND, L.P.
       
      By: Juniper HF Investors, LLC, its General Partner
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

     

     Page 16 of 17 Pages 
     

     

      JUNIPER HF INVESTORS, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER INVESTMENT COMPANY, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      By : /s/ Alexis P. Michas
     

    ALEXIS P. MICHAS

     

      By : /s/ John A. Bartholdson
      JOHN A. BARTHOLDSON

     

     Page 17 of 17 Pages 
     

     

    EXHIBIT A

     

    SCHEDULE OF TRANSACTIONS

     

     

    Reporting Person

    Date of Transaction

    Number of

    Shares Acquired

    Price

    Per Share*

    Low

    Price

    High

    Price

    Juniper Targeted Opportunity Fund, L.P. September 23, 2022 155,000 $14.10 $13.01 $15.05

     

    * The Price Per Share reported above is a weighted average price. The Shares were acquired in multiple transactions at a range of prices as reflected in the table above. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the ranges set forth above.

       
     

     

    EXHIBIT B


    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13D, dated September 26, 2022 (the “Schedule 13D”), with respect to the Common Stock, $0.01 par value per share, of Artivion, Inc., is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an exhibit to the Schedule 13D and each such amendment.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

     

    Dated: September 26, 2022

     

      JUNIPER TARGETED OPPORTUNITY FUND, L.P.
       
     

    By: Juniper HF Investors II, LLC, its

    General Partner

       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER HF INVESTORS II, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER TARGETED OPPORTUNITIES, L.P.
       
      By: Juniper Targeted Opportunity Investors, LLC, its General Partner
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER TARGETED OPPORTUNITY INVESTORS, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
     

     

      JUNIPER MULTI-STRATEGY FUND, L.P.
       
      By: Juniper HF Investors, LLC, its General Partner
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER HF INVESTORS, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      JUNIPER INVESTMENT COMPANY, LLC
       
      By : /s/ John A. Bartholdson
     

    Name: John A. Bartholdson

    Title: Managing Member

       
      By : /s/ Alexis P. Michas
     

    ALEXIS P. MICHAS

     

      By : /s/ John A. Bartholdson
      JOHN A. BARTHOLDSON

     

     

     

     

    Get the next $AORT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

      30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS.  Patients enrolled were at high risk for open surgical repair

      5/5/25 7:00:00 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

      ATLANTA, April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few minutes p

      4/21/25 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Financials

    Live finance-specific insights

    See more
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju

      2/24/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Third Quarter 2024 Financial Results

      Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basisNet loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug AdministrationEnrollment completed in NEXUS TRIOMPHE clinical

      11/7/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artivion Inc.

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      11/8/24 10:29:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Artivion Inc.

      SC 13G - ARTIVION, INC. (0000784199) (Subject)

      3/11/24 5:45:25 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/14/24 6:18:56 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Holloway Jean F exercised 19,092 shares at a strike of $21.55 and sold $425,510 worth of shares (18,020 units at $23.61), increasing direct ownership by 0.55% to 197,184 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:41:12 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Davis John E exercised 15,910 shares at a strike of $21.55 and sold $356,549 worth of shares (15,100 units at $23.61), increasing direct ownership by 0.39% to 208,778 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:32:23 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • President & CEO Mackin James P exercised 75,615 shares at a strike of $21.55, was granted 115,701 shares and sold $2,190,848 worth of shares (88,439 units at $24.77), increasing direct ownership by 13% to 865,283 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:18:53 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $AORT
    SEC Filings

    See more

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • May 23, 2023 - FDA Roundup: May 23, 2023

      For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

      5/23/23 4:06:19 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Artivion Inc.

      10-Q - ARTIVION, INC. (0000784199) (Filer)

      5/6/25 3:10:43 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/5/25 4:08:44 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Artivion Inc.

      DEFA14A - ARTIVION, INC. (0000784199) (Filer)

      4/1/25 4:49:56 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • JMP Securities initiated coverage on Artivion with a new price target

      JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

      10/23/24 6:17:27 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on Artivion with a new price target

      Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously

      9/27/22 11:06:42 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Artivion with a new price target

      Lake Street initiated coverage of Artivion with a rating of Buy and set a new price target of $32.00

      8/8/22 9:08:33 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Leadership Updates

    Live Leadership Updates

    See more
    • Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

      Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

      12/6/23 4:15:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Sequana Medical announces results of Special General Meeting of Shareholders

      PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

      6/26/23 12:00:00 PM ET
      $AORT
      $PHAR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Elizabeth Hoff Joins Artivion Board of Directors

      ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

      9/29/22 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care